Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SELLAS Life Sciences GroupSLS +1.88%25 Net Cash per Share is $0.55 as of Mar. 2026, which is 93% below its 10-year median of 7.75. GuruFocus rates SLS with a GF Score™ of 25/100. Among 801 Biotechnology companies, SELLAS Life Sciences Group ranks worse than 82.15% on this metric.
The historical rank and industry rank for SELLAS Life Sciences Group's Net Cash per Share or its related term are showing as below:
SLS'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.33 Med: 7.75 Max: 47.2
Current: 18.71
During the past 13 years, the highest Price-to-Net-Cash Ratio of SELLAS Life Sciences Group was 47.20. The lowest was 3.33. And the median was 7.75.
SLS's Price-to-Net-Cash is ranked worse than 82.15% of 801
companies
in the Biotechnology industry
Industry Median: 4.94
vs SLS: 18.71
SELLAS Life Sciences Group (NAS:SLS) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
SELLAS Life Sciences Group Net Cash per Share Related Terms
SELLAS Life Sciences Group Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group Net Cash per Share Chart
SLS vs IOVA, COAG, NUVB: Net Cash per Share Comparison
For the Biotechnology subindustry, SELLAS Life Sciences Group's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's Price-to-Net-Cash falls into.
SELLAS Life Sciences Group Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
SELLAS Life Sciences Group's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group (SLS) has a Net Cash per Share of $0.55 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on SELLAS Life Sciences Group and its competitors. This is 93% below median its historical median of 7.75. Over the past decade, SELLAS Life Sciences Group's Net Cash per Share has ranged from 3.33 to 47.20. According to the industry distribution chart, SELLAS Life Sciences Group ranks #658 out of 801 companies in the Biotechnology industry, placing it in the top 82.1%.
Is SELLAS Life Sciences Group's Net Cash per Share too high?
SELLAS Life Sciences Group's current Net Cash per Share of $0.55 is 93% below median its 10-year median of 7.75. Over the past 10 years, this metric has ranged from a low of 3.33 to a high of 47.20. The Biotechnology industry median Net Cash per Share is 4.94. SELLAS Life Sciences Group's value of $0.55 is 88.9% below this industry median. Based on the distribution chart, SELLAS Life Sciences Group ranks #658 out of 801 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's Net Cash per Share compare to IOVA and COAG?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #658 out of 801 companies for Net Cash per Share. This places SELLAS Life Sciences Group in the lower half of its industry. The industry median Net Cash per Share is 4.94. SELLAS Life Sciences Group's value of $0.55 is 88.9% below this benchmark. Historically, SELLAS Life Sciences Group's own Net Cash per Share has ranged from 3.33 to 47.20 over the past decade. While the company's 10-year median is 7.75 vs. the industry median of 4.94, SELLAS Life Sciences Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 4.94, based on 801 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SELLAS Life Sciences Group's current Net Cash per Share of $0.55 is 88.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median Net Cash per Share is 4.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current Net Cash per Share is $0.55, which is 93% below median its own 10-year median of 7.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current Net Cash per Share of $0.55. The current Net Cash per Share is $0.55, which is 93% below median its 10-year median of 7.75 and 88.9% below the Biotechnology industry median of 4.94. SELLAS Life Sciences Group's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current Net Cash per Share is $0.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score
Get the complete analysis for SLS
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
